Hematologic Oncology Update

51:43

Acute Myeloid Leukemia — Fifth Annual National...

Hematologic Oncology Update ·

2026/06/28

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:Introduction (0:00)Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)CME information and select publications

en

50:41

Myelofibrosis and Systemic Mastocytosis — Fifth...

Hematologic Oncology Update ·

2026/06/24

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:Introduction (0:00)Systemic Mastocytosis — Dr Hunter (9:33)Myelofibrosis — Dr Yacoub (29:40)CME information and select publications

en

47:05

Multiple Myeloma — Fifth Annual National General...

Hematologic Oncology Update ·

2026/06/18

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)CME information and select publications

en

55:24

Chronic Lymphocytic Leukemia — Fifth Annual National...

Hematologic Oncology Update ·

2026/06/16

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)CME information and select publications

en

01:59:30

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma...

Hematologic Oncology Update ·

2026/06/15

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof

en

58:42

Bruton Tyrosine Kinase Inhibitors for Chronic...

Hematologic Oncology Update ·

2026/05/23

Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.CME information and select publications here.

en

58:54

Acute Myeloid Leukemia — Year in Review Series on...

Hematologic Oncology Update ·

2026/04/20

Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.CME information and select publications here.

en

24:54

CELMoDs for Multiple Myeloma — Microlearning Activity...

Hematologic Oncology Update ·

2026/04/10

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.

en

24:50

Immune Thrombocytopenia — Microlearning Activity 4...

Hematologic Oncology Update ·

2026/04/01

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

en

24:29

CELMoDs for Multiple Myeloma — Microlearning Activity...

Hematologic Oncology Update ·

2026/03/23

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.

en

29:16

Immune Thrombocytopenia — Microlearning Activity 3...

Hematologic Oncology Update ·

2026/03/21

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

en

01:03:21

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia —...

Hematologic Oncology Update ·

2026/03/13

Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.

en

47:10

Chronic Lymphocytic Leukemia — An Interview with Prof...

Hematologic Oncology Update ·

2026/03/11

Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.CME information and select publications here.

en

19:21

Immune Thrombocytopenia — Microlearning Activity 2...

Hematologic Oncology Update ·

2026/03/09

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

en

24:25

Immune Thrombocytopenia — Microlearning Activity 1...

Hematologic Oncology Update ·

2026/03/04

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

en

57:58

Multiple Myeloma: Inside the Issue of Cereblon E3...

Hematologic Oncology Update ·

2026/02/18

Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.CME information and select publications here.

en

17:18

Relapsed/Refractory Multiple Myeloma — Microlearning...

Hematologic Oncology Update ·

2026/02/13

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

en

01:30:07

Immune Thrombocytopenia — ASH 2025 Review

Hematologic Oncology Update ·

2026/02/06

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here.

en

23:23

Relapsed/Refractory Multiple Myeloma — Microlearning...

Hematologic Oncology Update ·

2026/02/03

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

en

01:01:12

Bispecific Antibodies in the Management of Lymphoma —...

Hematologic Oncology Update ·

2026/01/21

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.

en

All Episodes

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media